Navigation Links
Varian, Inc. CEO to Speak at the Nasdaq OMX 22nd Investor Program
Date:11/20/2008

PALO ALTO, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Varian, Inc. (NasdaqGS: VARI) today announced that Garry W. Rogerson, President and CEO, will speak at the Nasdaq OMX 22nd Investor Program in London on Thursday, December 4, 2008 at 9:45 a.m. Eastern time.

A live webcast of the presentation will be publicly available from Varian, Inc.'s Web site at http://www.varianinc.com. Go to http://www.varianinc.com and click on "Investors." An archived replay will be available to the public from Varian, Inc.'s Web site for three months following the presentation.

Varian, Inc. is a leading worldwide supplier of scientific instruments and vacuum technologies for life science and industrial applications. The company provides complete solutions, including instruments, vacuum products, laboratory consumable supplies, software, training and support through its global distribution and support systems. Varian, Inc. employs approximately 3,900 people worldwide and operates manufacturing facilities in North America, Europe and Asia Pacific. Varian, Inc. had fiscal year 2008 sales of $1.0 billion, and its common stock is traded on the NASDAQ Global Select Market under the symbol "VARI." Further information is available on the company's Web site: http://www.varianinc.com.

     For More Information, Contact:
     Investor Relations
     Varian, Inc.
     650.424.5471
     ir@varianinc.com

'/>"/>
SOURCE Varian, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Varian, Inc. Reports First Quarter 2008 Results
2. New Chromatography Detectors From Varian, Inc. Extend the Range of Universal Detection for HPLC and LC/MS
3. New FTMS System From Varian, Inc. Offers Switchable LC and GC Sources and True Triple Quadrupole Capabilities
4. Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses
5. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
6. New FT-IR Spectrometer Series from Varian, Inc.
7. New Capillary Column From Varian, Inc. Offers Durability and Performance for High Temperature GC and GC/MS
8. James T. Glover Appointed to Board of Directors of Varian, Inc.
9. Varian, Inc. Reports Third Quarter 2008 Results
10. New Turbomolecular Pumping System From Varian, Inc. Delivers Portable, Dry, Ultra-high Vacuum.
11. New Dual Wavelength X-ray Diffractometer From Oxford Diffraction, Now a Part of Varian, Inc., Allows Increased Throughput for Challenging Single Crystal Analyses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
(Date:1/14/2014)... January 14, 2014 Kerr Corporation, a leading ... and additional how-to information about dual arch impressions on its ... Dual Arch Impressions,” the blog entry serves up a list ... houses a step-by-step demonstration by Dr. David Little as he ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in Altadena ... ideas for 2014 in production and sales of interactive ... high-quality, low-cost, DRM-free ebooks and to use the sales ... first major development will be bookstore sales in local ...
Breaking Biology Technology:RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... 21, 2011 MO BIO Laboratories, Inc., ... purification, announces the launch of the RTS DNase™ Kit, ... enzyme. (Photo: http://photos.prnewswire.com/prnh/20110921/LA65994 ) ... from RNA preparations while protecting valuable RNA samples from ...
... Silence Therapeutics plc (AIM: SLN) ("Silence", the "Group" or ... company, today announces the appointment of Tony Sedgwick PhD, ... Sedgwick will be based in Silence,s London office and ... Tony Sedgwick is an experienced biotechnology and pharmaceutical ...
... SANTA CRUZ, Calif., Sept. 20, 2011 SomaGenics, Inc., ... data on the efficacy of RNA interference (RNAi) therapeutics ... sshRNA platform. SomaGenics, along with its ... in a poster entitled "Synthetic Short shRNAs are Potent ...
Cached Biology Technology:MO BIO Laboratories, Inc. Launches the RTS DNase™ Kit 2Appointment of Chief Business Officer 2Appointment of Chief Business Officer 3SomaGenics' sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus 2SomaGenics' sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus 3
(Date:4/24/2014)... published in the Scientific Reports journal. , CSIC ... joint centre of CSIC and Pompeu Fabra University-UPF), explains: "When ... we saw that it did not match with the DNA ... the complete genome and to make a functional interpretation in ... Louis XVI". , The functional genome analysis was based ...
(Date:4/24/2014)... Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich have identified ... system to discriminate between viral and endogenous RNAs ... they take control of cellular metabolism and hijack ... This process is dependent on viral RNA molecules ... of RNA viruses) and/or newly synthesized in the ...
(Date:4/24/2014)... State University and the University of North Carolina at ... could help identify arterial plaque that is at high ... stroke. , At issue is the plaque that builds ... plaque are deemed "vulnerable," meaning that they are more ... heart attack or stroke. , "Existing state-of-the-art technologies are ...
Breaking Biology News(10 mins):The blood preserved in the pumpkin did not belong to Louis XVI 2Viral infections: Identifying the tell-tale patterns 2Viral infections: Identifying the tell-tale patterns 3New ultrasound device may add in detecting risk for heart attack, stroke 2
... researchers have shown natural radioactivity within DNA can alter ... The research, recently published in Biochimica et ... at natural radioactivity within human DNA on the atomic-scale. ... as well as in every living organism across the ...
... 2013 In the past decade, a single strain of ... become the main cause of bacterial infections in women and ... a study published today in the American Society for Microbiology,s ... resistant to antibiotics, the strain H30-Rx gained an unprecedented ability ...
... climate and biosphere modelling suggests that the length of time ... known as ,residence time, - is the key "uncertainty" in ... all life - will respond to higher CO2 levels and ... time in vegetation as the negative impacts of climate change ...
Cached Biology News:Radioactivity muddles the alphabet of DNA 2Epidemic of Escherichia coli infections traced to 1 strain of bacteria 2Epidemic of Escherichia coli infections traced to 1 strain of bacteria 34 degree rise will end vegetation 'carbon sink' 24 degree rise will end vegetation 'carbon sink' 3
Mouse monoclonal [MN-8C4] to zona radiata ( Abpromise for all tested applications). Antigen: Purified eggshell proteins (zona radiata proteins and small amounts of zona pellucida proteins) from ...
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Phospho-Chk1 (Ser296) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
Biology Products: